Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: A systematic review

BMJ Open

Volumn 5, Issue 3, 2015, Pages

  Price, Hilary I ^a   Agnew, Meghan D ^a   Gamble, John Michael ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; PHENFORMIN; PROTAMINE; TOLBUTAMIDE; ANTIDIABETIC AGENT;

ARTICLE; CARDIOVASCULAR MORBIDITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; COCHRANE LIBRARY; COHORT ANALYSIS; DATA BASE; DEATH; EMBASE; HEART DISEASE; HEART INFARCTION; HUMAN; MEDLINE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; MORTALITY; PRACTICE GUIDELINE;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84926434235     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006341     Document Type: Article

References (44)

1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2013;37:S1-212.
2. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care 2013;37:S14-80.
3. Filion KB, Joseph L, Boivin J-F, et al. Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf 2009;18:973-6.
4. Centers for Disease Control and Prevention. National Diabetes Statistics Report: estimates of diabetes and its burden in the United States, 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf (accessed 15 Jul 2014).
5. Ringborg A, Lindgren P, Yin DD, et al. Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes. Diabetes Metab 2010;36:198-203.
6. Canadian Agency for Drugs and Techologies in Health (CADTH). Current Utilization of Insulin Products in Canada. Canadian Optimal Medication Prescribing and Utilization Service (COMPUS), 2008. http://www.cadth.ca/media/pdf/compus-Current-Utilization-Report.pdf (accessed 15 Jul 2014).
7. Leiter LA, Berard L, Bowering CK, et al. Type 2 diabetes mellitus management in Canada: is it improving? Can J Diabetes 2013;37:82-9.
8. Boussageon R, Gamble JM, Gueyffier F, et al. Clinically relevant efficacy of insulin therapy in patients with type 2 diabetes. Therapie 2013;68:415-17.
9. Currie CJ, Johnson JA. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab 2012;14:1-4.
10. Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 2001;44(Suppl 2):S14-21.
11. Price HI, Agnew M, Gamble JM. Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review. PROSPERO 2014: CRD42014007631. http://wwwcrdyorkacuk/PROSPERO/display-recordasp?ID=CRD42014007631.
12. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011] ed: The Cochrane Collaboration, 2011.
13. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Secondary The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, 2014. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp
14. Raz I, Wilson PW, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381-6.
15. Knatterud GL, Klimt CR, Goldner MG, et al.; University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes VIII. Evaluation of insulin therapy: final report. Diabetes 1982;31:1-25.
16. Gamble J-M, Simpson SH, Eurich DT, et al. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab 2010;12:47-53.
17. Hall GC, McMahon AD, Carroll D, et al. Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease. PLoS ONE 2012;7:e49908.
18. Juhaeri J, Gao S, Dai WS. Incidence rates of heart failure, stroke, and acute myocardial infarction among type 2 diabetic patients using insulin glargine and other insulin. Pharmacoepidemiol Drug Saf 2009;18:497-503.
19. Kress S, Kostev K, Dippel FW, et al. Micro- and macrovascular outcomes in type 2 diabetic patients treated with insulin glulisine or human regular insulin: a retrospective database analysis. Int J Clin Pharmacol Ther 2012;50:821-9.
20. Rathmann W, Kostev K. Lower incidence of recorded cardiovascular outcomes in patients with type 2 diabetes using insulin aspart vs. those on human regular insulin: observational evidence from general practices. Diabetes Obes Metab 2013;15:358-63.
21. Rhoads GG, Kosiborod M, Nesto RW, et al. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. Am J Cardiol 2009;104:910-16.
22. Klimt CR, Knatterud GL, Meinert CL, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: I. Design, methods, and baseline results. Diabetes 1970;19:747-83.
23. Chaudhuri A, Dandona P, Fonseca V. Cardiovascular benefits of exogenous insulin. J Clin Endocrinol Metab 2012;97:3079-91.
24. Bretzel RG. Intensive insulin regimens: evidence for benefit. Int J Obes Relat Metab Disord 2004;28(Suppl 2):S8-13.
25. Dandona P, Aljada A, Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 2002;45:924-30.
26. Engel-Nitz NM, Martin S, Sun P, et al. Cardiovascular events and insulin therapy: a retrospective cohort analysis. Diabetes Res Clin Pract 2008;81:97-104.
27. Kumar A. Early use of insulin for beta cell preservation. J Assoc Physicians India 2007;55(Suppl):26-8.
28. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
29. Rensing KL, Reuwer AQ, Arsenault BJ, et al. Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing? Diabetes Obes Metab 2011;13:1073-87.
30. Nandish S, Bailon O, Wyatt J, et al. Vasculotoxic effects of insulin and its role in atherosclerosis: what is the evidence? Curr Atheroscler Rep 2011;13:123-8.
31. Currie CJ, Poole CD, Evans M, et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 2013;98:668-77.
32. Muis MJ, Bots ML, Grobbee DE, et al. Insulin treatment and cardiovascular disease; friend or foe? A point of view. Diabetic Med 2005;22:118-26.
33. Lebovitz HE. Insulin: potential negative consequences of early routine use in patients with type 2 diabetes. Diabetes Care 2011;34:S225-30.
34. Janka HU, Standl E. Hyperinsulinaemia as a possible risk factor of macrovascular disease in diabetes mellitus. An overview. Diabete Metab 1987;13:279-83.
35. Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008;17:753-9.
36. Draznin B. Mitogenic action of insulin: friend, foe or 'frenemy'?Diabetologia 2010;53:229-33.
37. Roumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 2014;311:2288-96.
38. Patel A, MacMahon S, Chalmers J, et al. Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
39. Gerstein HC, Miller ME, Byington RP, et al Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
40. Gerstein HC, Bosch J, Dagenais GR, et al. Origin Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-28.
41. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
42. Schernthaner G. Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr 2010;160:8-19.
43. Morrison A, Polisena J, Husereau D, et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 2012;28:138-44.
44. Moher D, Klassen TP, Schulz KF, et al. What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol 2000;53:964-72.